IRX THERAPEUTICS
IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.
IRX THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
1994-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.brooklynitx.com
Total Employee:
11+
Status:
Active
Contact:
(212) 582-1199
Total Funding:
127.67 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS ReCAPTCHA V2 AWS Global Accelerator DNSSEC GoDaddy Premium DNS
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Tollbridge Theapeutics Inc.
Tollbridge Theapeutics develops innovative therapies that use the immune system to fight cancer and other diseases.
Founder
Official Site Inspections
http://www.brooklynitx.com
- Host name: 143.198.171.144
- IP address: 143.198.171.144
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IRX Therapeutics"
IRX-2 - Drug Targets, Indications, Patents - Synapse
Originator Organization. IRX Therapeutics, Inc. Active Organization. University of Southern California National Cancer Institute Eterna Therapeutics LLC. Inactive Organization. ...See details»
Brooklyn ImmunoTherapeutics - Golden
Organization. Company attributes. Industry. Oncology. Therapeutics. 0. Immunotherapy. Cancer immunotherapy. ... Matt Angel. 0. Legal Name. Brooklyn ImmunoTherapeutics, Inc. Number of …See details»
brooklynitx.com - Whois.com
Oct 29, 2018 Whois Lookup for brooklynitx.com. Login Sign up My Account Logout; Domains. Registration. Register a Domain Get your domain name now Domain Suggestions Get help …See details»
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief …
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that …See details»
Eterna Therapeutics LLC - Drug pipelines, Patents, Clinical trials ...
Www.brooklynitx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. ... The statistics for drugs in the …See details»
Brooklyn ImmunoTherapeutics - VentureRadar
Website: http://brooklynitx.com/ Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company committed to developing IRX-2, a novel cytokine-based ...See details»
IRX Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Www.brooklynitx.com. Private Company | 1994 | New York, United States | 10-50 | www.brooklynitx.com. Last update 19 Sep 2024. Overview. Pipeline. Deal. Translational …See details»
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief
Jul 13, 2021 Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell …See details»
Brooklyn ImmunoTherapeutics Inc. - Cruelty Free Investing
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating …See details»
brooklynitx.com - Eterna Therapeutics Inc. – Ete... - Brooklynitx
Brooklynitx.com. BTX is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatme...See details»
22 Notable Biopharmaceutical Firms Based in New York - Inven
IAVI is an organization dedicated to researching and developing vaccines and antibodies for HIV, TB, emerging infectious diseases, and neglected diseases. They work towards disease …See details»
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to …
Oct 14, 2021 Ticker Symbol to Remain “BTX”NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a …See details»
Brooklyn ImmunoTherapeutics to Present at the Access to Giving …
Jul 12, 2021 For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Investor Relations Contact: CORE IR 516-222-2560 …See details»
IRX Therapeutics - Crunchbase Company Profile & Funding
IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer …See details»
News - investor.eternatx.com
For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Forward-Looking Statements. This press release contains forward-looking statements within …See details»
Brooklyn ImmunoTherapeutics Announces Establishment of New …
Apr 21, 2022 Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunologySAN DIEGO, April …See details»
Brooklyn ImmunoTherapeutics Completes Reverse Merger with …
Mar 25, 2021 For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Contacts. Media Relations: MacDougall Nicholas Chang …See details»
Brooklyn ImmunoTherapeutics Announces Changes to Executive …
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on …See details»
Eterna Therapeutics Inc share price: ERNA Stock Price live today
Nov 18, 2024 brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor …See details»
Brooklyn ImmunoTherapeutics Reports Inducement Grants
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that …See details»